OMOP has been transitioned from the Foundation for the National Institutes of Health to the Reagan-Udall Foundation for the Food and Drug Administration. OMOP has demonstrated the feasibility of establishing a common infrastructure which can accommodate observational data of different types (both claims and EHRs) from sources around the world, and successfully developed and executed large-scale statistical analyses capable of enabling active drug safety surveillance across prescription medications.
Now available from Drug Safety, Volume 36, Issue 1 Supplement, October 2013. A choice of original research articles discussing OMOP findings - "Studying the Science of Observational Research: Empirical Findings from the Observational Medical Outcomes Partnership."
The Reagan-Udall Foundation for the FDA is seeking a full-time Senior Director, IMEDS Methods Research to serve as the lead for methods research activities within the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program. The Senior Director will provide scientific and research expertise and leadership.